Alzamend Neuro, Inc. announced plans to start a phase II clinical study of AL001, focusing on its use for patients with bipolar disorder (BD), set to begin in the third quarter of 2025.
News-Medical.Net on MSN6d
Next-generation, inhaled COVID-19 vaccine enters phase-2 clinical trialResearchers at McMaster University have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine.
Receiving the FDA’s clearance to proceed with our Phase 2 clinical trial for TPST-1495, our second clinical program, in FAP marks an important step forward in developing new treatment options for ...
has completed the enrollment in the Phase 2 clinical study of DR10624 for the treatment of severe hypertriglyceridemia (SHTG) ("DR10624-201 study"). The DR10624-201 study is a randomized ...
We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology ... decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne ...
Researchers at McMaster University have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine.
Researchers across 14 medical centers in China, including Peking University People's Hospital, have found that an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback